Gene therapy for breast cancer

Shunji Takahashi, Yoshikazu Sugimoto

Research output: Contribution to journalArticle

Abstract

Gene therapy for advanced breast cancer is expected to be useful therapeutic approach. Strategies in ongoing clinical protocols can be divided into four: (1) suppression of oncogenes or transduction of tumor suppressor genes; (2) enhancement of immunological response; (3) transduction of suicide genes; (4) protection of bone marrow using drug resistance gene. We have started clinical study of multidrug resistance (mdr1) gene therapy. Advanced breast cancer patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with mdr1-transduced hematopoietic cells, and then were treated with docetaxel. 2 patients have been treated so far, and in vivo enrichment of mdr1-transduced cells with docetaxel treatment was seen. Both patients are in complete remission and have no apparent adverse effect from mdr1 gene transduction.

Original languageEnglish
Pages (from-to)476-482
Number of pages7
JournalNippon rinsho. Japanese journal of clinical medicine
Volume63
Issue number3
Publication statusPublished - 2005
Externally publishedYes

Fingerprint

docetaxel
Genetic Therapy
Breast Neoplasms
Genes
MDR Genes
Peripheral Blood Stem Cell Transplantation
Clinical Protocols
Tumor Suppressor Genes
Oncogenes
Drug Resistance
Suicide
Bone Marrow
Drug Therapy
Therapeutics

Cite this

Gene therapy for breast cancer. / Takahashi, Shunji; Sugimoto, Yoshikazu.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 63, No. 3, 2005, p. 476-482.

Research output: Contribution to journalArticle

@article{892638945890411daafb6f494d52ad70,
title = "Gene therapy for breast cancer",
abstract = "Gene therapy for advanced breast cancer is expected to be useful therapeutic approach. Strategies in ongoing clinical protocols can be divided into four: (1) suppression of oncogenes or transduction of tumor suppressor genes; (2) enhancement of immunological response; (3) transduction of suicide genes; (4) protection of bone marrow using drug resistance gene. We have started clinical study of multidrug resistance (mdr1) gene therapy. Advanced breast cancer patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with mdr1-transduced hematopoietic cells, and then were treated with docetaxel. 2 patients have been treated so far, and in vivo enrichment of mdr1-transduced cells with docetaxel treatment was seen. Both patients are in complete remission and have no apparent adverse effect from mdr1 gene transduction.",
author = "Shunji Takahashi and Yoshikazu Sugimoto",
year = "2005",
language = "English",
volume = "63",
pages = "476--482",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "3",

}

TY - JOUR

T1 - Gene therapy for breast cancer

AU - Takahashi, Shunji

AU - Sugimoto, Yoshikazu

PY - 2005

Y1 - 2005

N2 - Gene therapy for advanced breast cancer is expected to be useful therapeutic approach. Strategies in ongoing clinical protocols can be divided into four: (1) suppression of oncogenes or transduction of tumor suppressor genes; (2) enhancement of immunological response; (3) transduction of suicide genes; (4) protection of bone marrow using drug resistance gene. We have started clinical study of multidrug resistance (mdr1) gene therapy. Advanced breast cancer patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with mdr1-transduced hematopoietic cells, and then were treated with docetaxel. 2 patients have been treated so far, and in vivo enrichment of mdr1-transduced cells with docetaxel treatment was seen. Both patients are in complete remission and have no apparent adverse effect from mdr1 gene transduction.

AB - Gene therapy for advanced breast cancer is expected to be useful therapeutic approach. Strategies in ongoing clinical protocols can be divided into four: (1) suppression of oncogenes or transduction of tumor suppressor genes; (2) enhancement of immunological response; (3) transduction of suicide genes; (4) protection of bone marrow using drug resistance gene. We have started clinical study of multidrug resistance (mdr1) gene therapy. Advanced breast cancer patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with mdr1-transduced hematopoietic cells, and then were treated with docetaxel. 2 patients have been treated so far, and in vivo enrichment of mdr1-transduced cells with docetaxel treatment was seen. Both patients are in complete remission and have no apparent adverse effect from mdr1 gene transduction.

UR - http://www.scopus.com/inward/record.url?scp=18244363898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244363898&partnerID=8YFLogxK

M3 - Article

C2 - 15773348

AN - SCOPUS:18244363898

VL - 63

SP - 476

EP - 482

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 3

ER -